(Q36058652)

11 August 2017

1 reference

title

Current status of anti-SARS agents (English)

1 reference

11 August 2017

0 references

Shiro Shigeta

1

1 reference

PubMed ID

15739619

11 August 2017

Toshihiro Yamase

series ordinal

2

1 reference

11 August 2017

1 January 2005

1 reference

Antiviral Chemistry & Chemotherapy

11 August 2017

1 reference

11 August 2017

16

1 reference

11 August 2017

1

1 reference

11 August 2017

23-31

1 reference

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

11 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Treatment of SARS with human interferons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Hepatitis C virus replicons: potential role for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Antiviral and antimetabolic activities of neplanocins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

SARS treatment. Interferon shows promise in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Interferon-beta 1a and SARS coronavirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Identifying inhibitors of the SARS coronavirus proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Induction of inducible nitric oxide synthase expression by 18beta-glycyrrhetinic acid in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Severe acute respiratory syndrome: developing a research response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Severe acute respiratory distress syndrome (SARS): A critical care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Development of a standard treatment protocol for severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Management of severe acute respiratory syndrome: the Hong Kong University experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

mRNA cap-1 methyltransferase in the SARS genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Small molecules targeting severe acute respiratory syndrome human coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Autographa californica Nucleopolyhedrovirus orf69 Encodes an RNA Cap (Nucleoside-2'-O)-Methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600103

10.1177/095632020501600103

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15739619